Kornimate/medical-research-clean huggingface dataset:
impact of early ventilation in stroke outcomes in patients with sleep apnea after first ever stroke

Conditions: Stroke; Sleep Apnea

Summary: to evaluate the impact of early ventilation in stroke outcomes in patients with sleep apnea and first ever stroke, 1 month after stroke.

single-center, randomized, open label, parallel arm, prospective study in patients with sleep apnea after first-ever stroke. the study will consist of screening, baseline assessment, interventional period (consisting of a treatment period and follow-up visits), and a follow-up phone call. patients will be randomly assigned to asv (active) or control groups, within 4 days after the psg ii and will start the respective intervention in the same day. patients assigned to the active group will receive ventilatory support with asv (dreamstation bipap autosv®) during diurnal and nocturnal sleep, from study randomization until clinically indicated. patients assigned to control group will receive best medical treatment for stroke alone, including rehabilitation.

Eligibility criteria:
inclusion criteria: 1. written informed consent obtained from the participant or the legally acceptable representative, prior to any study-related procedure. 2. male or female between 18 and 80 years, inclusive, at the time of signing the informed consent. 3. admission to the hospital within 48 h of stroke symptoms onset. 4. ischemic first stroke diagnosis. 5. nihss ≥2 at screening. 6. sleep apnea with ahi ≥15. exclusion criteria: 1. csa with left ventricular ejection fraction ⩽45%. 2. ventilation treatment for sleep apnea diagnosis, prior to stroke. 3. risk of aspiration. 4. nasogastric feeding tube. 5. transient ischemic attack, hemorrhagic stroke or subarachnoid hemorrhage. 6. stroke due to a secondary cause (e.g. vascular malformation, vasculitis, brain tumor, head trauma, or predisposition to bleeding). 7. cardiorespiratory distress. 8. advanced chronic lung disease requiring supplemental oxygen. 9. concomitant central nervous system diseases such as dementia or multiple sclerosis. 10. uncontrolled psychosis or agitation. 11. glasgow coma scale (gcs) score \<10 at screening. 12. anosognosia, global or wernicke aphasia. 13. insufficient upper limbs function to use a mask and no overnight caregiver to help. 14. inability to attend to the rehabilitation program of the hospital. 15. pregnant and breast-feeding women. 16. participation in another clinical study (except a standard-of-care registry). 17. any other condition that, according to the investigator, renders the subject unsuitable for ventilation.

Keywords: stroke early ventilation sleep apnea
safety and immunogenicity of a sabin inactivated poliovirus vaccine.

Conditions: Polio and Post-Polio Syndrome

Summary: this study is a randomized, blinded and controlled phase ii study to evaluate the safety and immunogenicity of a sabin inactivated poliovirus vaccine (sipv) in infants. a total of 600 infants aged 2 months (60\~90 days) were randomized to receive five different vaccination regimens: three experimental groups (1, 2, and 3) received three doses of sipv with high, medium, and low d antigen content, respectively, on the month 0,1,2 schedule; two control groups (4 and 5) received three doses of conventional ipv (cipv, manufactured by sanofi pasteur) or sipv (manufactured by the institute of medical biology, the chinese academy of medical biology), respectively, on the same schedule. serum samples were collected before the 1st dose and 30 days after the 3rd dose vaccination to assess the immunogenicity. adverse events occurring within 30 days after each dose were collected to assess the safety.


Eligibility criteria:
inclusion criteria: * healthy volunteer aged 2 months (60\~90 days) old without prior vaccination of poliovirus and any contraindication for vaccination; * guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment; * complying with the requirement of the study protocol; * axillary temperature ≤ 37.0 °c; exclusion criteria: * preterm or low birth weight infants; * congenital malformation, developmental disorders, genetic defects, or severe malnutrition; * history of polio; * severe nervous system disease (epilepsy, seizures or convulsions) or mental illness; * history of allergy to any vaccine, or any ingredient of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc; * autoimmune disease or immunodeficiency/immunosuppressive; * bleeding disorder diagnosed by a doctor (e.g., coagulation factor deficiency, coagulation disorder, or platelet disorder) , or significant bruising or coagulopathy; * serious chronic diseases, respiratory diseases, cardiovascular diseases, liver or kidney diseases or skin diseases; * mother of the participant has hiv infection; * acute illness or acute exacerbation of chronic disease within the past 7 days; * had a high fever within the past 3 days (axillary temperature ≥ 38.0°c); * receipt of any subunit or inactivated vaccine within the past 7 day; * receipt of any live attenuated vaccine within the past 14 days; * receipt of any blood product within the past 3 months; * any other factor that, in the judgment of the investigator, suggesting the volunteer is unsuitable for this study;
the impact of pharmaceutical care on the infection control measures among hemodialytic patients

Conditions: Infection; Hemodialysis Patients

Summary: the study aims to assess the effectiveness of pharmaceutical care in reducing infection rates among hemodialysis patients with central venous (cv) lines. it will evaluate the role of clinical pharmacists in optimizing infection management and antimicrobial use. additionally, the study will examine the impact of pharmacist-led education on patient adherence to infection prevention and medication regimens. the role of pharmacists in reducing catheter-related bloodstream infections (crbsis) and other dialysis-related infections will also be investigated. finally, the study will evaluate patient satisfaction and quality of life improvements resulting from pharmaceutical interventions in infection management.

this interventional randomized controlled trial aims to investigate the impact of clinical pharmacist intervention on infection control measures among hemodialysis patients. a total of 70 patients will be randomly assigned to either an intervention group (35 patients) or a non-intervention (control) group (35 patients), and the study will be conducted over a period of six months. patients in the intervention group will receive pharmaceutical care in addition to standard care, with the clinical pharmacist identifying and resolving drug therapy problems (dtps) related to indication, effectiveness, safety, and compliance. specific infection control strategies in this group will include early referral to a nephrologist and patient education to reduce catheter use, thereby promoting timely transition to permanent vascular access options such as arteriovenous fistulas or grafts. in addition, topical antimicrobial ointments (e.g., polysporin triple antibiotic ointment, mupirocin, or medicinal honey) will be recommended for application at the catheter exit site during insertion and at each dialysis session to reduce catheter-related bloodstream infections. antiseptic lock solutions will be used to prevent catheter colonization and biofilm formation, while prophylactic antibiotic-anticoagulant lock solutions will be applied to further reduce bloodstream infection risk. the pharmacist will also ensure appropriate selection and monitoring of antimicrobial agents based on culture sensitivity results. meanwhile, patients in the non-intervention group will receive only conventional healthcare, with the researcher following them regularly to assess infection rates and identify any dtps without intervening. for both groups, regular monitoring will include laboratory tests such as cbc, c-reactive protein (crp) plasma viscosity, blood culture, and serum creatinine.

Eligibility criteria:
inclusion criteria: * patients in dialysis center with ckd * patients that can communicate with the researcher. exclusion criteria: * the patients who are not willing to participate in this study are going to be excluded.

Keywords: pharmaceutical care infection hemodialysis staphylococcus aureus
effectiveness of pain neuroscience education on clinical and psychosocial variables in chronic low back pain

Conditions: Chronic Low-back Pain

Summary: an educational intervention on the neurophysiology of chronic pain will be provided. the content of the intervention will be identical in the experimental groups (group and individual). the intervention has an active educational approach based on reconceptualizing the maladaptive beliefs that influence the fear-avoidance behavior of the participants through updated contents of the neuroscience of pain. the effects of the intervention will be compared between the groups and the influence of the social determinants of health on the effects will also be determined. the investigators hypothesize that there will be significant differences in favor of the group intervention group over the individual intervention groups. furthermore, the effects will be influenced by the social determinants of health in both experimental groups.


Eligibility criteria:
inclusion criteria: * non-specific low back pain ≥ 3 months without compromise of any lower limb. * average pain intensity ≥ 3/10 and ≤8/10 (according to the 0-10 numerical rating scale \[nrs\]) in the last month. exclusion criteria: * psychiatric, neurological or oncological diseases. * operated of some lumbar pathology * chronic low back pain due to a specific cause (lumbar stenosis, herniated disc, spinal deformity, fracture, spondylosis) * have received any modality of active or passive physical therapy for pain in the last two months, * previous experiences with pne

Keywords: pain neuroscience education physical therapy chronic pain
to evaluate the health effect of particular fatty acids profiles from eggs

Conditions: Abdominal Obesity

Summary: in a previous study, 24 volunteers consumed two conventional eggs or two eggs naturally enriched with omega 3, 5 and 7 every day for 3 months. it was shown that these eggs were well tolerated and that the omega enrichment led to a reduction in waist circumference of 3 cm in 3 months. the objective of omegasnack study was therefore to go further in the evaluation of these effects on waist circumference; 1) confirm the effects of these eggs on waist circumference when included in a snack, 2) determine whether this reduction in waist circumference is linked to a reduction in muscle and/or fat mass (subcutaneous and/or visceral) and 3) evaluate whether these effects are associated with a modification in the accumulation of ectopic fat in the muscle and/or liver.


Eligibility criteria:
inclusion criteria: * woman or man, aged of 18 to 75 years; * abdominal obesity: waist circumference for men \> 94cm and \> 80cm for women; * body mass index ≥ 25kg/m2 and ≤30kg/m2; * for women: use of effective contraception; * provision of signed and dated informed consent form; * stated willingness to comply with all study procedures and availability for the duration of the study; * french speaker. exclusion criteria: * uncontrolled systolic blood pressure \> 160/100 mmhg; * for premenopausal women: pregnant women or women planning to get pregnant within 3 months or lactating women; * for menopausal women: less than 6 months of menopause; * for perimenopausal women: presenting symptoms; * type ii diabetes (controlled or uncontrolled), type i diabetes; * medical history or actual cardiovascular disease (myocardial infarction, angina, transient ischemic attack, lower limb arteriopathy); * medical history or actual severe psychiatric, hepatic, pancreatic, kidney, pulmonary or gastrointestinal problem * thyroid disorder; * cancer \< 3 years before the screening visit; * smokers or who have stopped smoking within the last 6 months before the screening visit; * subject presenting allergy or food intolerance to eggs; * subjects who are not able to understand and follow study procedures; * drug addiction problem (regular consumption); * recent change of body weight \> 7% (\< 2 months before the inclusion); * within 1 month before the screening visit, change in the chronic (\> 7 days in a row) intake or dosage of drug(s) or product(s) modifying the glucose and/or lipid metabolism; * current or recent (\< 2 months before the screening visit) intake of dietary supplements rich in n-3 polyunsaturated fatty acid (including tablets, pills, capsules, enriched-oils); * vegan diet; * consumption of fish \> 3 times per week; * women who drink more than 2 glasses of alcohol per day (\> 20 g of alcohol per day or \> 140g/week) or men who drink more than 3 glasses of alcohol per day (\> 30 g of alcohol per day or more than 210g/week); * ldl \> 159 mg/dl or total cholesterol \> 239 mg/dl; * subjects having participated to another clinical trial \< 1 month before the screening test visit.
effectiveness of closed loop stimulation (cls) with his bundle lead placement

Conditions: Sinus Node Dysfunction

Summary: this study is a prospective, non-randomized pilot study looking to evaluate the effectiveness of closed loop stimulation (cls) in sinus node dysfunction patients with his bundle placement. patients with sinus node dysfunction who have previously received a biotronik pacemaker with his bundle lead placement as part of routine care will be recruited for the study. a hand-grip exercise will be performed at the conclusion of bicycle exercise testing in order to assess the performance of cls during isometric exercise. after the study exercise testing is completed, data will be collected from the pacemaker.


Eligibility criteria:
inclusion criteria: * documented sinus node dysfunction * biotronik pacemaker implanted with his bundle lead placement for standard indications * implanted at least 30 days * cls has been enabled for at least 7 days or will be programmed on for at least 7 days prior to exercise test * leads and device are functioning appropriately exclusion criteria: * inability to complete treadmill/bicycle exercise test * planned surgical revision or replacement of the device and/or leads * patients who are unwilling or unable to provide informed consent
fuzheng yiliu-1010

Conditions: Colorectal Cancer Stage II and III

Summary: real world study was used to evaluate the therapeutic effect of fuzheng anti-tumor therapy on colorectal cancer patients in stage ii and iii after surgery and standard chemotherapy, and the prediction model of dominant population of fuzheng anti-tumor therapy was constructed by using real-world data and gene expression profile data.


Eligibility criteria:
inclusion criteria: 1. the age of the patients was 18-75 years old; 2. radical resection of colorectal cancer (negative margin) was performed; 3. patients with stage ii high risk and stage iii colorectal cancer confirmed by histology; 4. no liver, peritoneal or distant metastasis was found; 5. patients with colorectal cancer who received standard chemotherapy or radiotherapy after operation and had no recurrence or metastasis at the end of radiotherapy and chemotherapy; 6. ecog (eastern cooperative oncology group) score was 0-1; kps score was 70 or above; 7. liver function: sgot and sgpt were less than 1.5 times of normal value, bilirubin was less than 1.5 mg / dl; 8. renal function: creatinine \< 1.8mg/dl. exclusion criteria: 1. allergic to the drug of this scheme; 2. pregnant or lactating women with fertility requirements during the study period; 3. severe hypertension, coronary heart disease, diabetes and so on, which are under control for half a year due to cardiovascular accident and poor drug control, are accompanied with other uncontrollable benign diseases such as lung, kidney, liver, infection, etc; 4. participate in other studies before and during treatment; 5. there was a history of other malignant tumors or multi-source tumors within one year; 6. chronic hepatitis b or c (high copy viral dna) or activity in hiv infection history or active phase; 7. patients with tuberculosis or seizures who need to be treated (e.g. steroids or antiepileptic therapy).
vascular endothelial growth factor (vegf) trap-eye: investigation of efficacy and safety in wet age-related macular degeneration (amd)

Conditions: Macular Degeneration

Summary: this study is a phase iii, double-masked, randomized, study of the efficacy and safety of vegf trap-eye in patients with neovascular age-related macular degeneration. approximately 1200 patients will be randomized in europe, asia, japan, australia and south america.

data of this trial ("view 2") was pooled with data of a sister trial ("view 1", nct00509795), and an integrated analyses of the combined data was performed.

Eligibility criteria:
inclusion criteria: * signed informed consent. * men and women \>/=50 years of age. * active primary or recurrent subfoveal cnv lesions secondary to amd, including juxtafoveal lesions that affect the fovea as evidenced by fluorescein angiography (fa) in the study eye. * etdrs best-corrected visual acuity letter score of 73 to 25 (= acuity of 20/40 to 20/320) in the study eye at 4 meters. * willing, committed, and able to return for all clinic visits and complete all study-related procedures. * able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) understand and willing to sign the informed consent form. exclusion criteria: * any prior ocular (in the study eye) or systemic treatment or surgery for neovascular amd, except dietary supplements or vitamins. * any prior or concomitant therapy with another investigational agent to treat neovascular amd in the study eye. * any prior treatment with anti-vegf agents in the study eye. * total lesion size \>12 disc areas (30.5 mm, including blood, scars and neovascularization) as assessed by fa in the study eye. * subretinal hemorrhages that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye (if the blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible cnv). * scar or fibrosis making up \>50% of the total lesion in the study eye. * scar, fibrosis, or atrophy involving the center of the fovea in the study eye. * presence of retinal pigment epithelial tears or rips involving the macula in the study eye. * history of any vitreous hemorrhage within 4 weeks prior to visit 1 in the study eye. * presence of other causes of cnv in the study eye. * prior vitrectomy in the study eye. * history of retinal detachment or treatment or surgery for retinal detachment in the study eye. * any history of macular hole of stage 2 and above in the study eye. * any intraocular or periocular surgery within 3 months of day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as it is unlikely to interfere with the injection. * history or clinical evidence of diabetic retinopathy, diabetic macular edema or any retinal vascular disease other than amd in either eye.

Keywords: eye diseases vision impairment and blindness eyes and vision seniors neovascular age-related macular degeneration (amd) retinal disease
precision diets for diabetes prevention

Conditions: Pre Diabetes; Insulin Resistance; Diabetes Mellitus, Type 2

Summary: with this study the investigators want to understand the physiological differences for people developing pre-diabetes and diabetes. the investigators hypothesize that different individuals go through different paths in the development of the disease. by understanding the personal mechanism for developing disease, the investigators will find a personalized approach to prevent that development. the investigators are also hoping to be able to find a biomarker that will pinpoint to the particular defect and thus, diagnose the problem at an earlier stage and have the information to give personalized diet recommendations to prevent the development of diabetes more effectively.

at present, individuals with prediabetes or diabetes are grouped together as a single entity, but almost certainly they represent a mix of different gene-environment interactions that lead to one of four dominant physiologic mechanisms underlying their dysglycemia. 1- liver insulin resistance, 2- muscle insulin resistance, 3- impaired insulin secretion, 4- impaired incretin hormone secretion. gaps that we are addressing here are extremely important - first, we will define a composite biomarker to identify different subphenotypes of prediabetes based on the four known physiologic mechanisms that contribute differentially in each individual to glucose elevations, which we hypothesize will also be reflected in their "glucotype". importantly, because both continuous glucose monitor and administration of standardized meal testing and metabolic tests are not practical in the clinic, the development of a composite biomarker comprised of select multi-omics measures and clinical variables will enable clinicians and possibly patients (without clinician) to easily identify the specific diet that will yield optimal health results.

Eligibility criteria:
inclusion criteria: * be 18 years of age or older; * not be pregnant, if female; exclusion criteria: * have major organ disease, hypertension defined as \>160/100, pregnant/lactating, diabetogenic medications, malabsorptive disorders like celiac sprue, others, heavy alcohol use, use of weight loss medications or specific diets, weight change \> 2 kg in the last three weeks, history of bariatric surgery. * any medical condition that physicians believe would interfere with study participation or evaluation of results. * mental incapacity a nd/or cognitive impairment on the part of the patient that would preclude adequate understanding of, or cooperation with, the study protocol.
development of automated analysis to electroencephelogram (eeg) data in patients treated at the sagol hyperbaric medicine and research center at the years 2017-2019.

Conditions: Healthy; CVA; Hemorrhage; TBI (Traumatic Brain Injury); Concussion, Brain; Fibromyalgia; ABD; Adhd; Dementia; Mci; Cognitive Impairment; Cognitive Decline; MS (Multiple Sclerosis)

Summary: delphi software developed for the analysis of eeg recordings in response to magnetic stimulation in relation to clinical data.

collection of eeg data, recorded at sagol center for hyperbaric medicine and research in the years of 2017-2019 of patients arriving to be treated at the hyperbaric chamber before,during and after treatments. eeg was recorded of patients during cognitive tests, resting state and during magnetic stimulation as a part of other array of tests performed at the sagol center. anonymous eeg data along with mri scans, pet-ct, spect, cognitive tests, medical history and medications will be transferred to quantalx neuroscience ltd. quantalx neuroscience is intending to use the above mentioned data in order to improve delphi, an algorithm for the analysis of eeg recordings in response to magnetic stimulation.

Eligibility criteria:
inclusion criteria: * subjects over the age of 18. * subjects that performed at least one eeg test as a part of their hyperbaric treatment at sagol center asaf-harophe. exclusion criteria: * subjects with no eeg test or that their eeg recording is in pure quality, not allowing analysis of the data.